GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Investments And Advances

TheraCryf (FRA:8EV) Investments And Advances : €0.00 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Investments And Advances?

TheraCryf's Investments And Advances for the quarter that ended in Sep. 2023 was €0.00 Mil.


TheraCryf Investments And Advances Historical Data

The historical data trend for TheraCryf's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Investments And Advances Chart

TheraCryf Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TheraCryf Semi-Annual Data
Mar13 Mar14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

TheraCryf Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


TheraCryf (FRA:8EV) Business Description

Traded in Other Exchanges
Address
Congleton Road, Suite 24G13- Block 24, Alderley Park, Nether Alderley, GBR, SK10 4TG
Evgen Pharma PLC is a UK-based clinical-stage drug development company. The company is focused on the development of sulforaphane-based compounds. Its core technology is Sulforadex, which synthesis and stabilizes the naturally occurring compound sulforaphane. Geographically, the company operates only in the United Kingdom. It is engaged in the treatment of breast cancer and Subarachnoid Haemorrhage.

TheraCryf (FRA:8EV) Headlines

No Headlines